Table 2.

Baseline characteristics of the included patient cohorts and controls

Cohort	Total N	Male (%)	Mean AAO	Early onset (%)	Goldman score						Site of sample origin
					1	2	3	3.5	4	4.5	NHNN cognitive centre	NHS cognitive disorder clinics	National prion clinic	NHNN Clinical neurogenetics	Cardiff university
AD	1052	400 (38.0%)	57.7	78	73 (6.9%)	30 (2.9%)	66 (6.3%)	103 (9.8%)	245 (23.3%)	535 (50.9%)	873 (83.0%)	103 (9.8%)	1 (0.1%)	75 (7.1%)	0
FTD	794	419 (52.8%)	58.4	61	72 (9.1%)	43 (5.4%)	50 (6.3%)	64 (8.1%)	298 (37.5%)	267 (33.6%)	645 (81.2%)	45 (5.7%)	0	104 (13.1%)	0
Prion	299	121 (40.5%)	57.6	55	34 (11.4%)	6 (2.0%)	11 (3.7%)	15 (5.0%)	207 (69.2%)	26 (8.7%)	2 (0.7%)	0	296 (99.0%)	1 (0.3%)	0
DemMot	639	280 (43.8%)	55.8	70	24 (3.8%)	12 (1.9%)	18 (2.8%)	84 (13.2%)	215 (33.7%)	286 (44.8%)	535 (83.7%)	17 (2.7%)	0	87 (13.6%)	0
Controls	457	237 (51.9%)	76.6	–	4 (0.9%)	0	0	2 (0.4%)	0	451 (98.7%)	6 (1.3%)	0	3 (0.7%)	0	448 (98.0%)
All	3241	1457 (45.0%)	60.3	59	207 (6.4%)	91 (2.8%)	145 (4.5%)	268 (8.3%)	965 (29.8%)	1565 (48.3%)	2061 (63.6%)	165 (5.1%)	300 (9.3%)	267 (8.2%)	448 (13.8%)

The 3241 samples were made up by 1052 AD patients, 794 FTD patients, 299 prion patients and 639 patients with dementia with motor symptoms, as well as 457 elderly controls. This table shows the distribution of each cohort in numbers and percentages for their baseline characteristics sex, age at onset (AAO), early- or late-onset disease (over or under 65 AAO), Goldman score [30] and the site of the sample origin, i.e., whether it was a retrospective sample chosen from the collection of a cognitive centre, a prospectively recruited sample from a Memory Clinic at a primary referral centre, a sample from the National Prion Clinic or a control sample